Structure-Promiscuity Relationship Puzzles—Extensively Assayed Analogs with Large Differences in Target Annotations
暂无分享,去创建一个
Jürgen Bajorath | Ye Hu | Swarit Jasial | Erik Gilberg | J. Bajorath | Ye Hu | Swarit Jasial | Erik Gilberg
[1] Baris E. Suzek,et al. The Universal Protein Resource (UniProt) in 2010 , 2009, Nucleic Acids Res..
[2] J. Bajorath,et al. Chemical Substitutions That Introduce Activity Cliffs Across Different Compound Classes and Biological Targets , 2010, J. Chem. Inf. Model..
[3] J. Bajorath,et al. Activity landscape representations for structure-activity relationship analysis. , 2010, Journal of medicinal chemistry.
[4] María Martín,et al. The Universal Protein Resource (UniProt) in 2010 , 2010 .
[5] J. Baell,et al. Chemistry: Chemical con artists foil drug discovery , 2014, Nature.
[6] Dimitrios H Roukos,et al. Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. , 2011, Pharmacogenomics.
[7] J. Irwin,et al. An Aggregation Advisor for Ligand Discovery. , 2015, Journal of medicinal chemistry.
[8] J. Baell,et al. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.
[9] George Papadatos,et al. The ChEMBL bioactivity database: an update , 2013, Nucleic Acids Res..
[10] John J. Irwin,et al. ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..
[11] E. Jacoby,et al. Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.
[12] Ian A. Watson,et al. Rules for identifying potentially reactive or promiscuous compounds. , 2012, Journal of medicinal chemistry.
[13] B. Shoichet. Screening in a spirit haunted world. , 2006, Drug discovery today.
[14] P. Nurse,et al. Reductionism: The ends of understanding , 1997, Nature.
[15] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[16] Olivier Sperandio,et al. FAF-Drugs3: a web server for compound property calculation and chemical library design , 2015, Nucleic Acids Res..
[17] B. Shoichet,et al. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.
[18] Jürgen Bajorath,et al. Determining the Degree of Promiscuity of Extensively Assayed Compounds , 2016, PloS one.
[19] Daniel J. Warner,et al. Matched molecular pairs as a medicinal chemistry tool. , 2011, Journal of medicinal chemistry.
[20] R. Iyengar,et al. Systems approaches to polypharmacology and drug discovery. , 2010, Current opinion in drug discovery & development.
[21] Jürgen Bajorath,et al. MMP-Cliffs: Systematic Identification of Activity Cliffs on the Basis of Matched Molecular Pairs , 2012, J. Chem. Inf. Model..
[22] Jürgen Bajorath,et al. High-resolution view of compound promiscuity. , 2013, F1000Research.
[23] Jameed Hussain,et al. Computationally Efficient Algorithm to Identify Matched Molecular Pairs (MMPs) in Large Data Sets , 2010, J. Chem. Inf. Model..
[24] Jürgen Bajorath,et al. Identification and analysis of promiscuity cliffs formed by bioactive compounds and experimental implications , 2017 .
[25] John M. Barnard,et al. Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..
[26] Jürgen Bajorath,et al. Recent progress in understanding activity cliffs and their utility in medicinal chemistry. , 2014, Journal of medicinal chemistry.
[27] G. Müller,et al. Medicinal chemistry of target family-directed masterkeys. , 2003, Drug discovery today.
[28] J. Bajorath,et al. Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.
[29] Evan Bolton,et al. PubChem's BioAssay Database , 2011, Nucleic Acids Res..
[30] Marvin Johnson,et al. Concepts and applications of molecular similarity , 1990 .
[31] Jürgen Bajorath,et al. Matched molecular pair analysis of small molecule microarray data identifies promiscuity cliffs and reveals molecular origins of extreme compound promiscuity. , 2012, Journal of medicinal chemistry.